

Antibody Discovery Services and Platforms Market (5th Edition): Distribution by Type of Service Offered (Antigen Designing, Hit Generation, Lead Selection, Lead Optimization, Lead Characterization), Antibody Discovery Method (Hybridoma based, Library based, Single Cell based, Transgenic Animal based), Type of Antibody Generated (Monoclonal Antibodies, Bispecific Antibodies and Others), Nature of Antibody Generated (Chimeric, Human, Humanized and Murine), Type of Therapeutic Areas (Cardiovascular Disorders, Immunological Disorders, Infectious Disorders, Neurological Disorders, Oncological Disorders and Others) and Key Geographies (North America, Europe, Asia, Latin America, Middle East and North Africa and Rest of the World): Industry Trends and Global Forecasts, 2023-2035

<https://marketpublishers.com/r/A56233267417EN.html>

Date: September 2023

Pages: 525

Price: US\$ 4,799.00 (Single User License)

ID: A56233267417EN

Abstracts

The global antibody discovery services and platforms market is expected to reach USD 1.6 billion by 2023 anticipated to grow at a CAGR of 12% during the forecast period 2023-2035.

Developing drugs, from discovery to market, usually spans 10-15 years and involves

substantial investments, often exceeding \$2 billion. Unfortunately, more than 90% of drug candidates don't pass clinical trials. To streamline this process, reduce timelines, and manage the risk, pharmaceutical companies are outsourcing aspects of their discovery work to specialized contract research organizations (CROs). Collaborating with antibody CROs helps companies in the antibody discovery market optimize resources, cut costs, and tap into a global scientific talent pool, enhancing efficiency and success rates in bringing new antibody-based therapies to market.

Monoclonal antibody-based therapies, like Orthoclone OKT3® approved in 1986, have advanced significantly. They've diversified in formats, undergone engineering improvements, and benefited from innovative discovery methods. Over 160 monoclonal antibodies have been approved for various diseases, including cancer, chronic inflammatory conditions, infectious diseases, and cardiovascular ailments. Recently, therapies like ELREXFIO™, TALVEY™, Rystiggo®, COLUMVI®, and EPKINLY™ were approved between May 2023 and August 2023. Due to the complexity of discovering these antibodies, many companies choose to license specialized antibody discovery platforms and technologies. The growing demand for antibody-based therapies and the preference for outsourcing indicate a significant expected expansion in antibody discovery services and platforms in the future.

Report Coverage

The report extensively examines the antibody discovery market, categorizing it by service type, discovery method, antibody type, nature, therapeutic fields, and key geographical regions.

It thoroughly analyzes market growth influencers such as drivers, restraints, opportunities, and challenges.

The report evaluates both advantages and obstacles within the market landscape and offers insights into the competitive environment among top market players.

Revenue forecasts for market segments are provided across six major regions.

Detailed insights into the systematic research approach, methodologies, assumptions, and quality control measures employed ensure the accuracy and reliability of findings.

Analysis encompasses historical trends, currency fluctuations, foreign exchange impacts, recession effects, and inflation measurements affecting antibody discovery services and platforms.

It provides a concise overview of the present market status and forecasts the short, mid, and long-term evolution of the antibody discovery services and platforms market.

Comprehensive coverage of historical context, structural details, isotypes, mechanisms of action, and applications of antibodies, with emphasis on monoclonal, bispecific, and polyclonal types.

Detailed examination and comparison of discovery methods, tracking the developmental trends of monoclonal antibodies from murine to human variants over the past three decades.

Analysis of over 160 active service providers based on various parameters such as establishment year, company size, location, services offered, discovery methods, animal models used, types of antibodies, and purposes.

Comparative evaluation of companies based on experience, platforms, services offered, discovery methods, antibody formats, application areas, and regional capabilities.

In-depth profiles of companies providing antibody discovery services, including company overview, recent developments, and future outlook.

Examination of 290+ platforms based on antibody types, discovery methods, animal models, establishment year, company size, and headquarters location.

Assessment of leading market players considering supplier power, platform specifications, antibody compatibility, and deals signed between 2015-2023.

Detailed information about companies offering access/licenses to their antibody discovery platforms or technologies, including company overview, platform details, recent developments, and future outlook.

Evaluation of partnerships established within the antibody discovery market from 2021-2023, with descriptions of partnership models adopted by stakeholders.

Examination of investments in the antibody discovery market from 2016-2023 across various financing stages and sources.

Insights into cash flows, net present values, and scenarios of upfront, milestone, and royalty payments between licensors and licensees.

Detailed discussion on industry-specific trends, market drivers, challenges, key players, and influencing factors in antibody humanization services.

Presentation of detailed profiles of top-selling drugs in 2022, including historical sales, discovery processes, and methods.

Discussion on upcoming antibody therapeutics and technologies expected to impact the industry's evolution in the coming decade.

Key Market Companies

Ablexis

Antibody Solutions

ChemPartner

Creative Biolabs

GenScript

Genmab

Harbour BioMed

ImmunoPrecise

MabSilico

Myrio Therapeutics

Nona Biosciences

Rockland Immunochemicals

Synbio technologies

WuXi Biologics

Contents

1. PREFACE

- 1.1. Introduction
- 1.2. Project Objectives
- 1.3. Scope of the Report
- 1.4. Inclusions and Exclusions
- 1.5. Key Questions Answered
- 1.6. Chapter Outlines

2. RESEARCH METHODOLOGY

- 2.1. Chapter Overview
- 2.2. Research Assumptions
- 2.3. Project Methodology
- 2.4. Forecast Methodology
- 2.5. Robust Quality Control
- 2.6. Key Considerations
 - 2.6.1. Demographics
 - 2.6.2. Economic Factors
 - 2.6.3. Government Regulations
 - 2.6.4. Supply Chain
 - 2.6.5. COVID Impact / Related Factors
 - 2.6.6. Market Access
 - 2.6.7. Healthcare Policies
 - 2.6.8. Industry Consolidation
- 2.7. Key Market Segmentation

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

- 3.1. Chapter Overview
- 3.2. Market Dynamics
 - 3.2.1. Time Period
 - 3.2.1.1. Historical Trends
 - 3.2.1.2. Current and Forecasted Estimates
 - 3.2.2. Currency Coverage
 - 3.2.2.1. Overview of Major Currencies Affecting the Market
 - 3.2.2.2. Impact of Currency Fluctuations on the Industry

3.2.3. Foreign Exchange Impact

3.2.3.1. Evaluation of Foreign Exchange Rates and their Impact on Market

3.2.3.2. Strategies for Mitigating Foreign Exchange Risk

3.2.4. Recession

3.2.4.1. Historical Trends Analysis of Past Recessions and Lessons Learnt

3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market

3.2.5. Inflation

3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy

3.2.5.2. Potential Impact of Inflation on the Market Evolution

4. EXECUTIVE SUMMARY

5. INTRODUCTION

5.1. Chapter Overview

5.2. Structure of Antibodies

5.3. History of Antibody Development

5.4. Antibody Isotypes

5.5. Mechanism of Action of Antibodies

5.6. Classification of Antibodies

5.6.1. Monoclonal Antibodies

5.6.2. Polyclonal Antibodies

5.6.3. Bispecific Antibodies

5.7. Applications of Antibodies

5.8. Concluding Remarks

6. ANTIBODY DISCOVERY: PROCESS AND METHODS

6.1. Chapter Overview

6.2. Antibody Discovery Process

6.2.1. Target Selection and Validation

6.2.2. Hit Generation

6.2.3. Lead Selection

6.2.4. Lead Optimization

6.2.4.1. Humanization

6.2.4.2. Affinity Maturation

6.2.4.3. Fc Engineering

6.2.5. Lead Characterization

- 6.2.6. Candidate Selection
- 6.3. Antibody Discovery Methods
 - 6.3.1. Hybridoma Technology-based Method
 - 6.3.2. In vitro Display Method
 - 6.3.2.1. Phage Display
 - 6.3.2.2. Yeast Display
 - 6.3.2.3. Ribosomal Display
 - 6.3.3. Transgenic Animal-based Method
 - 6.3.4. Single B Cell-based Method
 - 6.3.5. Advantages and Disadvantages of Existing Antibody Discovery Techniques
- 6.4. Evolution of Monoclonal Antibodies
 - 6.4.1. Fully Human Monoclonal Antibodies
- 6.5. Concluding Remarks

7. ANTIBODY DISCOVERY SERVICE PROVIDERS: MARKET LANDSCAPE

- 7.1. Chapter Overview
- 7.2. Antibody Discovery Service Providers: List of Industry Players
 - 7.2.1. Analysis by Year of Establishment
 - 7.2.2. Analysis by Company Size
 - 7.2.3. Analysis by Location of Headquarters
 - 7.2.4. Analysis by Type of Antibody Discovery Services Offered
 - 7.2.5. Analysis by Type of Antibody Discovered
 - 7.2.6. Analysis by Type of Antibody Discovery Method
 - 7.2.7. Analysis by Animal Model Used
 - 7.2.8. Analysis by Type of Antibody Discovered and Type of Antibody Discovery Method
 - 7.2.9. Analysis by Type of Antibody Discovery Services and Location of Headquarters
 - 7.2.10. Analysis by Application Area

8. COMPANY COMPETITIVENESS ANALYSIS

- 8.1. Chapter Overview
- 8.2. Assumptions and Key Parameters
- 8.3. Methodology
- 8.4. Competitiveness Analysis: Companies Grouped based on Company Size
 - 8.4.1. Very Small Companies Offering Antibody Discovery Services
 - 8.4.2. Small Companies Offering Antibody Discovery Services
 - 8.4.3. Mid-sized Companies Offering Antibody Discovery Services

- 8.4.4. Large Companies Offering Antibody Discovery Services
- 8.5. Antibody Discovery Service Providers: Regional Capability
 - 8.5.1. Antibody Discovery Service Providers based in North America
 - 8.5.2. Antibody Discovery Service Providers based in Europe
 - 8.5.3. Antibody Discovery Service Providers based in Asia

9. COMPANY PROFILES: ANTIBODY DISCOVERY SERVICE PROVIDERS

- 9.1. Chapter Overview
- 9.2. Antibody Discovery Service Providers in North America
 - 9.2.1. Abwiz Bio
 - 9.2.1.1. Company Overview
 - 9.2.1.2. Recent Developments and Future Outlook
 - 9.2.2. Abzena
 - 9.2.2.1. Company Overview
 - 9.2.2.2. Recent Developments and Future Outlook
 - 9.2.3. Aragen Life Sciences
 - 9.2.3.1. Company Overview
 - 9.2.3.2. Recent Developments and Future Outlook
 - 9.2.4. Capralogics
 - 9.2.4.1. Company Overview
 - 9.2.4.2. Recent Developments and Future Outlook
 - 9.2.5. Creative Biolabs
 - 9.2.5.1. Company Overview
 - 9.2.5.2. Financial Information
 - 9.2.5.3. Recent Developments and Future Outlook
 - 9.2.6. DetaiBio
 - 9.2.6.1. Company Overview
 - 9.2.6.2. Recent Developments and Future Outlook
 - 9.2.7. ImmunoPrecise Antibodies
 - 9.2.7.1. Company Overview
 - 9.2.7.2. Financial Information
 - 9.2.7.3. Recent Developments and Future Outlook
 - 9.2.8. Integral Molecular
 - 9.2.8.1. Company Overview
 - 9.2.8.2. Recent Developments and Future Outlook
 - 9.2.9. Syd Labs
 - 9.2.9.1. Company Overview
 - 9.2.9.2. Recent Developments and Future Outlook

9.3. Antibody Discovery Service Providers in Europe

9.3.1. BIOTEM

9.3.1.1. Company Overview

9.3.1.2. Recent Developments and Future Outlook

9.3.2. FairJourney Biologics

9.3.2.1. Company Overview

9.3.2.2. Recent Developments and Future Outlook

9.3.3. Fusion Antibodies

9.3.3.1. Company Overview

9.3.3.2. Recent Developments and Future Outlook

9.3.4. Proteogenix

9.3.4.1. Company Overview

9.3.4.2. Recent Developments and Future Outlook

9.3.5. RD Biotech

9.3.5.1. Company Overview

9.3.5.2. Recent Developments and Future Outlook

9.4. Antibody Discovery Service Providers in Asia

9.4.1. ABGENEX

9.4.1.1. Company Overview

9.4.1.2. Recent Developments and Future Outlook

9.4.2. ChemPartner

9.4.2.1. Company Overview

9.4.2.2. Recent Developments and Future Outlook

9.4.3. Viva Biotech

9.4.3.1. Company Overview

9.4.3.2. Financial Information

9.4.3.3. Recent Developments and Future Outlook

9.4.4. WuXi Biologics

9.4.4.1. Company Overview

9.4.4.2. Financial Information

9.4.4.3. Recent Developments and Future Outlook

10. ANTIBODY DISCOVERY TECHNOLOGIES: MARKET LANDSCAPE

10.1. Chapter Overview

10.2. Antibody Discovery: List of Technologies

10.2.1. Analysis by Type of Antibody Discovery Method

10.2.2. Analysis by Type of Antibody Discovered

10.2.3. Analysis by Animal Model Used

10.2.4. Analysis by Type of Antibody Discovery Method and Type of Antibody Discovered

10.2.5. Analysis by Type of Antibody Discovery Method and Location of Headquarters
10.3. Antibody Discovery Technologies: Developer Landscape

10.3.1. Analysis by Year of Establishment

10.3.2. Analysis by Company Size

10.3.3. Analysis by Location of Headquarters

10.3.4. Most Active Players: Analysis by Number of Technologies

11. TECHNOLOGY COMPETITIVENESS ANALYSIS

11.1. Chapter Overview

11.2. Assumptions and Key Parameters

11.3. Methodology

11.4. Antibody Discovery Technologies: Competitiveness Analysis

11.4.1. Antibody Discovery Technologies Offered by Companies based in North America

11.4.2. Antibody Discovery Technologies Offered by Companies based in Europe

11.4.3. Antibody Discovery Technologies Offered by Companies based in Asia and Rest of the World

12. COMPANY PROFILES: ANTIBODY DISCOVERY PLATFORM PROVIDERS

12.1. Chapter Overview

12.2. Ablexis

12.2.1. Company Overview

12.2.2. Antibody Discovery Platform Portfolio

12.2.3. Recent Developments and Future Outlook

12.3. Creative Biolabs

12.3.1. Company Overview

12.3.2. Antibody Discovery Platform Portfolio

12.3.3. Recent Developments and Future Outlook

12.4. Genmab

12.4.1. Company Overview

12.4.2. Financial Information

12.4.3. Antibody Discovery Platform Portfolio

12.4.4. Recent Developments and Future Outlook

12.5. Harbour Biomed

12.5.1. Company Overview

- 12.5.2. Financial Information
- 12.5.3. Antibody Discovery Platform Portfolio
- 12.5.4. Recent Developments and Future Outlook
- 12.6. Immunome
 - 12.6.1. Company Overview
 - 12.6.2. Antibody Discovery Platform Portfolio
 - 12.6.3. Recent Developments and Future Outlook
- 12.7. Isogenica
 - 12.7.1. Company Overview
 - 12.7.2. Antibody Discovery Platform Portfolio
 - 12.7.3. Recent Developments and Future Outlook
- 12.8. Ligand Pharmaceuticals
 - 12.8.1. Company Overview
 - 12.8.2. Financial Information
 - 12.8.3. Antibody Discovery Platform Portfolio
 - 12.8.4. Recent Developments and Future Outlook
- 12.9. Kymab
 - 12.9.1. Company Overview
 - 12.9.2. Antibody Discovery Platform Portfolio
 - 12.9.3. Recent Developments and Future Outlook
- 12.10. MorphoSys
 - 12.10.1. Company Overview
 - 12.10.2. Financial Information
 - 12.10.3. Antibody Discovery Platform Portfolio
 - 12.10.4. Recent Developments and Future Outlook

13. PARTNERSHIPS AND COLLABORATIONS

- 13.1. Chapter Overview
- 13.2. Partnership Models
- 13.3. List of Partnerships and Collaborations
 - 13.3.1. Analysis by Year of Partnership
 - 13.3.2. Analysis by Type of Partnership
 - 13.3.3. Analysis by Year of Partnership and Type of Partner
 - 13.3.4. Analysis by Type of Antibody
 - 13.3.5. Most Active Players: Analysis by Number of Partnerships
 - 13.3.6. Most Popular Technologies: Analysis by Number of Partnerships
 - 13.3.7. Analysis by Geography
 - 13.3.8. Intracontinental and Intercontinental Agreements

14. FUNDING AND INVESTMENT ANALYSIS

14.1. Chapter Overview

14.2. Types of Funding

14.3. Antibody Discovery Service and Platform Providers: Funding and Investment

14.3.1. Analysis by Year of Funding

14.3.2. Analysis by Type of Funding

14.3.3. Analysis of Amount Invested by Year of Funding

14.3.4. Analysis by Year-wise Number of Funding Instances and Funding Amount

14.3.5. Most Active Players: Analysis by Number of Funding Instances

14.3.6. Most Active Players: Analysis by Amount Invested

14.3.7. Leading Investors: Analysis by Number of Funding Instances

14.3.8. Analysis by Year-wise Number of Funding Instances and Type of Player

14.3.9. Analysis by Year-wise Amount Invested and Type of Player

14.3.10. Analysis of Number of Funding Instances by Year of Establishment and Type of Player

14.3.11. Analysis by Geography

14.4. Concluding Remarks

15. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES

15.1. Chapter Overview

15.2. Market Drivers

15.3. Market Restraints

15.4. Market Opportunities

15.5. Market Challenges

15.6. Conclusion

16. GLOBAL ANTIBODY DISCOVERY SERVICES MARKET

16.1. Chapter Overview

16.2. Assumptions and Methodology

16.3. Global Antibody Discovery Services Market, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)

16.3.1. Scenario Analysis

16.4. Key Market Segmentations

16..5. DYNAMIC DASHBOARD

17. ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE OF SERVICE OFFERED

17.1. Chapter Overview

17.2. Key Assumptions and Methodology

17.3. Antigen Designing: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)

17.4. Hit Generation: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)

17.5. Lead Selection: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)

17.6. Lead Optimization: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)

17.7. Lead Characterization: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)

17.8. Data Triangulation and Validation

18. ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE OF ANTIBODY DISCOVERY METHOD

18.1. Chapter Overview

18.2. Key Assumptions and Methodology

18.3. Phage Display: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)

18.4. Yeast Display: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)

18.5. Hybridoma Method: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)

18.6. Transgenic Animal based Method: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)

18.7. Single Cell based Method: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)

18.8. Other Antibody Discovery Methods: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)

18.9. Data Triangulation and Validation

19. ANTIBODY DISCOVERY SERVICES MARKET, BY NATURE OF ANTIBODY

DISCOVERED

- 19.1. Chapter Overview
- 19.2. Key Assumptions and Methodology
- 19.3. Humanized: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
- 19.4. Human: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
- 19.5. Chimeric: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
- 19.6. Murine: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
- 19.7. Data Triangulation and Validation

20. ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE OF THERAPEUTIC AREAS

- 20.1. Chapter Overview
- 20.2. Key Assumptions and Methodology
- 20.3. Oncological Disorders: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
- 20.4. Immunological Disorders: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
- 20.5. Infectious Disorders: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
- 20.6. Neurological Disorders: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
- 20.7. Cardiovascular Disorders: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
- 20.8. Other Disorders: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
- 20.9. Data Triangulation and Validation

21. ANTIBODY DISCOVERY SERVICES MARKET, BY KEY GEOGRAPHIES

- 21.1. Chapter Overview
- 21.2. Key Assumptions and Methodology
- 21.3. North America: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
- 21.4. Europe: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
- 21.5. Asia: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
- 21.6. Latin America: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)

21.7. Middle East and North Africa: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)

21.8. Rest of the World: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)

21.9. Data Triangulation and Validation

22. GLOBAL ANTIBODY DISCOVERY TECHNOLOGIES MARKET

22.1. Chapter Overview

22.2. Assumptions and Methodology

22.3. Global Antibody Discovery Technologies Market, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)

22.3.1. Scenario Analysis

22.4. Key Market Segmentations

22.5. Dynamic Dashboard

23. ANTIBODY DISCOVERY TECHNOLOGIES MARKET, BY TYPE OF ANTIBODY DISCOVERED

23.1. Chapter Overview

23.2. Key Assumptions and Methodology

23.3. Monoclonal Antibodies: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)

23.4. Bispecific Antibodies: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)

23.5. Other Antibodies: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)

23.6. Data Triangulation and Validation

24. ANTIBODY DISCOVERY TECHNOLOGIES MARKET, BY KEY GEOGRAPHIES

24.1. Chapter Overview

24.2. Key Assumptions and Methodology

24.3. North America: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)

24.4. Europe: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)

24.5. Asia: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)

24.6. Data Triangulation and Validation

25. LICENSING DEAL STRUCTURE

- 25.1. Chapter Overview
- 25.2. Key Parameters
- 25.3. Assumptions and Methodology
 - 25.3.1. Overall Cash Flow for Licensee Companies
 - 25.3.1.1. Investments Made by a Licensee
 - 25.3.1.2. Revenues Earned by a Licensee
 - 25.3.2. Overall Cash Flow for Licensor Companies
 - 25.3.2.1. Investments Made by a Licensor
 - 25.3.2.2. Revenues Earned by a Licensor
- 25.4. Key Analytical Outputs
 - 25.4.1. Scenario 1: Variation of Upfront and Milestone Payments
 - 25.4.2. Scenario 2: Variation of Upfront Payments and Sales-based Royalties
 - 25.4.3. Scenario 3: Variation of Milestone Payments and Sales-based Royalties

26. SWOT ANALYSIS: ANTIBODY HUMANIZATION SERVICE PROVIDERS

- 26.1. Chapter Overview
- 26.2. Antibody Humanization and Affinity Maturation Service and Platform Providers: List of Players
- 26.3. Antibody Humanization Service Providers: SWOT Analysis
 - 26.3.1. Strengths
 - 26.3.2. Weaknesses
 - 26.3.3. Opportunities
 - 26.3.4. Threats

27. CASE IN POINT: DRUG DISCOVERY PROCESSES OF TOP SELLING ANTIBODIES

- 27.1. Chapter Overview
- 27.2. Humira® (Adalimumab)
 - 27.2.1. Drug Overview
 - 27.2.2. Discovery Process and Method
 - 27.2.3. Historical Sales
- 27.3. Keytruda® (Pembrolizumab)
 - 27.3.1. Drug Overview
 - 27.3.2. Discovery Process and Method
 - 27.3.3. Historical Sales

- 27.4. Stelara® (Ustekinumab)
 - 27.4.1. Drug Overview
 - 27.4.2. Discovery Process and Method
 - 27.4.3. Historical Sales
- 27.5. Dupixent® (Dupilumab)
 - 27.5.1. Drug Overview
 - 27.5.2. Discovery Process and Method
 - 27.5.3. Historical Sales
- 27.6. Opdivo® (Nivolumab)
 - 27.6.1. Drug Overview
 - 27.6.2. Discovery Process and Method
 - 27.6.3. Historical Sales

28. FUTURE GROWTH OPPORTUNITIES IN ANTIBODY DISCOVERY

- 28.1. Chapter Overview
- 28.2. Anticipated Shift from Monoclonal Antibodies to Other Novel Antibody Formats
- 28.3. Technological Advancements to Overhaul Conventional Antibody Discovery Processes
- 28.4. Transition to CADD-based Approaches to Help Achieve Better Operational Efficiencies
- 28.5. Rising Demand for Antibody-based Treatment Options for Non-Oncological Indications
- 28.6. Future Growth Opportunities in the Asia and Rest of the World
- 28.7. Expected Increase in Number of Collaborations and Licensing Activity
- 28.8. Concluding Remarks

29. CONCLUSION

30. EXECUTIVE INSIGHTS

- 30.1. Chapter Overview
- 30.2. Antibody Solutions
 - 30.2.1. Company Snapshot
 - 30.2.2. Interview Transcript
- 30.3. Adimab
 - 30.3.1. Company Snapshot
 - 30.3.3. Interview Transcript
- 30.4. ImmunoPrecise Antibodies

- 30.4.1. Company Snapshot
- 30.4.3. Interview Transcript
- 30.5. Anonymous
 - 30.5.1. Anonymous, Chief Business Officer (Q3 2023)
- 30.6. Abveris, Acquired by Twist Biosciences
 - 30.6.1. Company Snapshot
 - 30.6.2. Interview Transcript
- 30.7. Nidus BioSciences
 - 30.7.1. Company Snapshot
 - 30.7.2. Interview Transcript
- 30.8. AvantGen
 - 30.8.1. Company Snapshot
 - 30.8.2. Interview Transcript
- 30.9. Single Cell Technology
 - 30.9.1. Company Snapshot
 - 30.9.2. Interview Transcript
- 30.10. Distributed Bio
 - 30.10.1. Company Snapshot
 - 30.10.2. Interview Transcript
- 30.11. AbCellera
 - 30.11.1. Company Snapshot
 - 30.11.2. Interview Transcript
- 30.12. AbGenics Life Sciences
 - 30.12.1. Company Snapshot
 - 30.12.2. Interview Transcript
- 30.13. CDI Laboratories
 - 30.13.1. Company Snapshot
 - 30.13.2. Interview Transcript
- 30.14. AP Biosciences
 - 30.14.1. Company Snapshot
 - 30.14.2. Interview Transcript
- 30.15. YUMAB
 - 30.15.1. Company Snapshot
 - 30.15.2. Interview Transcript
- 30.16. Antibody Solutions
 - 30.16.1. Company Snapshot
 - 30.16.2. Interview Transcript
- 30.17. Ligand Pharmaceuticals
 - 30.17.1. Company Snapshot

- 30.17.2. Interview Transcript
- 30.18. LakePharma
 - 30.18.1. Company Snapshot
 - 30.18.2. Interview Transcript

31. APPENDIX 1: TABULATED DATA

32. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATION

I would like to order

Product name: Antibody Discovery Services and Platforms Market (5th Edition): Distribution by Type of Service Offered (Antigen Designing, Hit Generation, Lead Selection, Lead Optimization, Lead Characterization), Antibody Discovery Method (Hybridoma based, Library based, Single Cell based, Transgenic Animal based), Type of Antibody Generated (Monoclonal Antibodies, Bispecific Antibodies and Others), Nature of Antibody Generated (Chimeric, Human, Humanized and Murine), Type of Therapeutic Areas (Cardiovascular Disorders, Immunological Disorders, Infectious Disorders, Neurological Disorders, Oncological Disorders and Others) and Key Geographies (North America, Europe, Asia, Latin America, Middle East and North Africa and Rest of the World): Industry Trends and Global Forecasts, 2023-2035

Product link: <https://marketpublishers.com/r/A56233267417EN.html>

Price: US\$ 4,799.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A56233267417EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970